Moomoo AI 已提取核心信息
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
2023年12月31日，唐资本合伙人有限责任公司以及唐资本管理有限责任公司和唐凯文共同报告了对Altimmune, Inc.275万股股票的共同投票权和处置权。s 普通股，占公司同类股的 5.1%。该修正案在向美国证券交易委员会提交的附表13G/A文件中披露。这些股票由申报实体和个人实益持有，百分比基于Altimmune在2023年11月3日发布的季度报告中公布的53,728,871股已发行普通股。该文件表明，该所有权的目的不是改变或影响Altimmune, Inc.的控制权。唐资本管理有限责任公司经理Kevin Tang于2024年2月14日认证该信息是真实和正确的。
2023年12月31日，唐资本合伙人有限责任公司以及唐资本管理有限责任公司和唐凯文共同报告了对Altimmune, Inc.275万股股票的共同投票权和处置权。s 普通股，占公司同类股的 5.1%。该修正案在向美国证券交易委员会提交的附表13G/A文件中披露。这些股票由申报实体和个人实益持有，百分比基于Altimmune在2023年11月3日发布的季度报告中公布的53,728,871股已发行普通股。该文件表明，该所有权的目的不是改变或影响Altimmune, Inc.的控制权。唐资本管理有限责任公司经理Kevin Tang于2024年2月14日认证该信息是真实和正确的。
有用
没用